Last weekend, members of the Alnylam team joined the Association of Black Cardiologists, Inc. (ABC) to celebrate 50 years of championing health equity. We’re proud to stand alongside ABC in advancing heart health and addressing the unique experiences of different communities in cardiovascular care. #ABC50Years
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 252,907 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-24), Fast Company (Best Workplaces for Innovators 2020-24) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
Ziggy’s parents, Jackie and Colin, knew something wasn’t right. Their persistence helped lead to their newborn son’s diagnosis of primary #hyperoxaluria type 1 (#PH1), a genetic #raredisease. See how Jackie and Colin advocated for Ziggy: https://bit.ly/4077xSE
-
In the same way that software developers use an operating system like iOS or Android to quickly and easily create new apps, Alnylam scientists use our RNA interference (RNAi) therapeutics platform to rapidly develop investigational medicines targeting a broad spectrum of diseases. Read about how this RNAi therapeutic ‘operating system’ is rewriting drug discovery in this new Nature Portfolio article: https://lnkd.in/e5Aqgzvb (sponsored content; intended for U.S. audiences only) #RNAi #RNAiTherapeutics #RNAinterference #siRNA #DrugDevelopment #IamRNAiScienceCurious
-
We believe that all patients, regardless of their diagnosis, have the potential to benefit from the promise that RNA interference (RNAi) therapeutics hold to silence disease to amplify life. That's why we've pioneered this innovative approach to treating disease, and why we're working to bring the RNAi-based medicines to as many patients as possible. Learn more at https://bit.ly/4dfwNLQ #SilenceDisease #AmplifyLife #RNAi #RNAiTherapeutics
-
Healthcare Professionals: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type. Learn more about testing for AHP. https://bit.ly/40s1cBs
-
-
Today is #WorldHeartDay! ❤️ At Alnylam, our commitment to cardiovascular health extends beyond groundbreaking science. We're dedicated to developing innovative therapies for patients where current options are limited, and equally passionate about supporting the patient community every step of the way.
Today is #WorldHeartDay! For 25 years, we have come together on 29 September to make heart health a global priority. Right now, people around the world are missing out on time with loved ones, the chance to protect their own health, and the opportunities afforded by more sustainable local health systems. Too often, this is due to the premature and preventable loss caused by cardiovascular disease, the world’s biggest killer. That's why, this year, we tell the world #DontMissABeat: every heartbeat counts, and our mission remains as urgent as ever. Join us: http://worldheartday.org/
-
Last week, we partnered with Alzheimer's Association® to hear from patients and caregivers for #AlzheimersAwarenessMonth. Moving stories from Dan Hogan and Alnylam’s Cindy Courtney highlighted both the challenges and resilience behind the diagnosis, offering a space to #AskAboutAlzheimers and foster understanding, support, and advocacy.
-
The fight against Alzheimer's is personal for many of us at Alnylam, including our colleague Kevin Sloan. His grandmother’s Alzheimer’s story is unique, yet all too common. This #WorldAlzMonth, we stand with patients and their families to #AskAboutAlzheimers and raise awareness of this disease, while tirelessly researching the potential of RNAi therapeutics to treat neurological conditions. Discover the full story: https://bit.ly/4nKuynw
-
Sparking curiosity in #science, one secret message at a time! Our uLearn with Alnylam team had an amazing day at the Cambridge Science Carnival helping families discover the chemistry behind invisible ink. Watching kids' faces light up as their hidden messages magically appeared through chemical reactions was pure joy! Each family took home their own invisible ink creations to continue the scientific fun. #CambridgeScienceFestival
-
We’re growing our Commercial field team and have several key Business Account Executive roles open for those early in their sales career journey. If you have a "challenge accepted" mindset and are inspired by the chance to put patients first, work alongside passionate colleagues and shape the future of medicine, we want to connect! Featured Openings: 🔗 Midwest (Chicago) https://bit.ly/3Ksk1Px 🔗 Northwest (Seattle/Portland) https://bit.ly/467WD2q 🔗 Northern California (East Bay to Sacramento) https://bit.ly/4mlfRWW Learn more about our other open roles and what makes Alnylam a top employer: https://bit.ly/3Kas43t #ChallengeAccepted #BiotechJobs
-